Literature DB >> 17109514

Cancer gene therapy targeting angiogenesis: an updated review.

Ching-Chiu Liu1, Zan Shen, Hsiang-Fu Kung, Marie C M Lin.   

Abstract

Since the relationship between angiogenesis and tumor growth was established by Folkman in 1971, scientists have made efforts exploring the possibilities in treating cancer by targeting angiogenesis. Inhibition of angiogenesis growth factors and administration of angiogenesis inhibitors are the basics of anti-angiogenesis therapy. Transfer of anti-angiogenesis genes has received attention recently not only because of the advancement of recombinant vectors, but also because of the localized and sustained expression of therapeutic gene product inside the tumor after gene transfer. This review provides the up-to-date information about the strategies and the vectors studied in the field of anti-angiogenesis cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109514      PMCID: PMC4087336          DOI: 10.3748/wjg.v12.i43.6941

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  81 in total

1.  Interleukin-18 acts as an angiogenesis and tumor suppressor.

Authors:  R Cao; J Farnebo; M Kurimoto; Y Cao
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

Review 2.  Gene therapy of cancer based on interleukin 12.

Authors:  Bruno Sangro; Ignacio Melero; Cheng Qian; Jesus Prieto
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

3.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

4.  Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor.

Authors:  K Kurachi; E W Davie; D J Strydom; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

5.  Phase I study of recombinant human endostatin in patients with advanced solid tumors.

Authors:  Roy S Herbst; Kenneth R Hess; Hai T Tran; Jennifer E Tseng; Nizar A Mullani; Chusilp Charnsangavej; Timothy Madden; Darren W Davis; David J McConkey; Michael S O'Reilly; Lee M Ellis; James Pluda; Waun K Hong; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

6.  Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation.

Authors:  Takashi Nishikawa; Rajagopal Ramesh; Anupama Munshi; Sunil Chada; Raymond E Meyn
Journal:  Mol Ther       Date:  2004-06       Impact factor: 11.454

7.  Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family.

Authors:  F R Steele; G J Chader; L V Johnson; J Tombran-Tink
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

8.  [Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases].

Authors:  Shan-wen Zhang; Shao-wen Xiao; Chang-qing Liu; Yan Sun; Xing Su; Dong-ming Li; Gang Xu; Yong Cai; Guang-ying Zhu; Bo Xu; You-yong Lü
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2003-12-10

Review 9.  Current strategies in cancer gene therapy.

Authors:  Anas El-Aneed
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

10.  Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.

Authors:  Amir Abdollahi; Kenneth E Lipson; Axel Sckell; Heike Zieher; Frank Klenke; Daniel Poerschke; Alexandra Roth; Xiaohong Han; Martin Krix; Marc Bischof; Philip Hahnfeldt; Hermann-Josef Grone; Juergen Debus; Lynn Hlatky; Peter E Huber
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  9 in total

Review 1.  Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Authors:  Elena M Glinka
Journal:  Tumour Biol       Date:  2015-04-01

2.  Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer.

Authors:  Keng-Li Lan; Fu Ou-Yang; Sang-Hue Yen; How-Ling Shih; Keng-Hsin Lan
Journal:  Clin Exp Metastasis       Date:  2010-04-07       Impact factor: 5.150

3.  Imaging techniques used for the real-time assessment of angiogenesis in digestive cancers.

Authors:  Adrian Săftoiu; Peter Vilmann
Journal:  World J Gastroenterol       Date:  2011-01-07       Impact factor: 5.742

4.  Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides.

Authors:  Christina Coleman; Danielle Levine; Raj Kishore; Gangjian Qin; Tina Thorne; Erin Lambers; Sharath P Sasi; Mina Yaar; Barbara A Gilchrest; David A Goukassian
Journal:  J Oncol       Date:  2010-06-28       Impact factor: 4.375

5.  Inhibition of angiogenesis as a new therapeutic target in the treatment of lepromatous leprosy.

Authors:  Mohamed El-Khalawany; Dalia Shaaban; Maha Sultan; Fatma Abd Alsalam
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-12-29

6.  Regulation of vascular endothelial cell polarization and migration by Hsp70/Hsp90-organizing protein.

Authors:  Jingyu Li; Xiaodong Sun; Zaizhu Wang; Li Chen; Dengwen Li; Jun Zhou; Min Liu
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

7.  Cancer cell: using inflammation to invade the host.

Authors:  José-Ignacio Arias; María-Angeles Aller; Jaime Arias
Journal:  Mol Cancer       Date:  2007-04-16       Impact factor: 27.401

8.  The Major Prognostic Features of Nuclear Receptor NR5A2 in Infiltrating Ductal Breast Carcinomas.

Authors:  Li-Yun Chang; Li-Yu D Liu; Don A Roth; Wen-Hung Kuo; Hsiao-Lin Hwa; King-Jen Chang; Fon-Jou Hsieh
Journal:  Int J Genomics       Date:  2015-08-23       Impact factor: 2.326

9.  EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner.

Authors:  Qingling Wang; Yangyang Tang; Tianyuan Wang; Hong-Li Yang; Xinyue Wang; Hongru Ma; Peng Zhang
Journal:  Oncol Lett       Date:  2018-06-01       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.